Litcius/Paper detail

Current and future status of JAK inhibitors

Donal P McLornan, Janet E Pope, Jason Gotlib, Claire N Harrison

2021The Lancet303 citationsDOI

Topics & Concepts

Janus kinaseMedicineSTAT proteinJanus kinase 2JAK-STAT signaling pathwayTofacitinibRuxolitinibDiseaseCancer researchMyeloproliferative DisordersSTAT3KinaseInflammatory bowel diseaseImmunologyActivator (genetics)BioinformaticsstatRheumatoid arthritisJanus kinase 1Signal transductionInternal medicineCytokine Signaling Pathways and InteractionsMyeloproliferative Neoplasms: Diagnosis and TreatmentMast cells and histamine
Current and future status of JAK inhibitors | Litcius